Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ
Background: Neutralizing anti-drug antibodies (ADA) can greatly reduce the efficacy of biopharmaceuticals used to treat patients with multiple sclerosis (MS). However, the biological factors pre-disposing an individual to develop ADA are poorly characterized. Thus, there is an unmet clinical need fo...
Main Authors: | Kirsty E. Waddington, Artemis Papadaki, Leda Coelewij, Marsilio Adriani, Petra Nytrova, Eva Kubala Havrdova, Anna Fogdell-Hahn, Rachel Farrell, Pierre Dönnes, Inés Pineda-Torra, Elizabeth C. Jury |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01527/full |
Similar Items
-
Disrupted Lipid Metabolism in Multiple Sclerosis: A Role for Liver X Receptors?
by: Inés Pineda-Torra, et al.
Published: (2021-04-01) -
Transcriptional Regulation of T-Cell Lipid Metabolism: Implications for Plasma Membrane Lipid Rafts and T-Cell Function
by: George A. Robinson, et al.
Published: (2017-11-01) -
Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults
by: Chinar R. Parikh, et al.
Published: (2021-06-01) -
Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
by: Nicky Dunn, et al.
Published: (2020-10-01) -
Prediction of MHC class I binding peptides, using SVMHC
by: Elofsson Arne, et al.
Published: (2002-09-01)